EUVIMEDEUVIMED entdecken
Crossref

Exploring the prognostic significance of antiphospholipid antibody in acute myocardial infarction: insights from clinical study and mechanism

Dabuxilite Bayartaikishigtai, Shengqiang Pei, Zixin Chen, Fengming Luo, Jie Xu, Danyu Song, Dongze Yu, Qiang Xu, Ximing Wang, Jianru Liu, Yang Zhang, Zhou Zhou

Journal of Thrombosis and Haemostasis · 2026-04 · 24 (4) · 1425-1437

DOI: 10.1016/j.jtha.2025.12.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-04. Verfasst von Dabuxilite Bayartaikishigtai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center of Laboratory Medicine, Beijing Key Laboratory of Cardiovascular Disease Warning and Diagnosis, State Key Laboratory of Cardiovascular Disease…. Hauptthemen laut MEDLINE: Antibodies, Antiphospholipid, Myocardial Infarction, Antiphospholipid Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Beijing Natural Science Foundation, National Natural Science Foundation of China, Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Acute myocardial infarction (AMI) remains a major cause of morbidity and mortality. Besides traditional cardiovascular risk factors, autoimmune components such as antiphospholipid antibodies (aPL) have been implicated, but their prognostic role in AMI is unclear. OBJECTIVES: This study investigated the prognostic significance of aPL in patients with AMI and explored potential mechanisms. METHODS: This study consecutively enrolled 777 patients with AMI and detected aPL. Cox proportional hazard models assessed cardiovascular event risk. For mechanistic insights, an antiphospholipid syndrome (APS) myocardial infarction mouse model was developed, and bulk RNA sequencing was performed on human coronary artery endothelial cells (HCAECs) stimulated with APS immunoglobulin G. RESULTS: Compared with the aPL-negative group, patients in the aPL-positive group were significantly younger (62.0 [54.0-69.0] vs 52.0 [44.0-60.0] years; P < .001). aPL-positive AMI group had higher incidence of thrombosis (199 [27.3%] vs 22 [46.8%]; P = .007) and fewer traditional risk factors such as hypertension and hyperlipidemia. During a mean follow-up of 18.8 months, aPL positivity was significantly associated with future cardiovascular events (adjusted hazards ratio, 2.28; 95% CI, 1.26-4.12; P = .006). In the mouse model, the APS group exhibited accelerated disease progression and higher thrombosis rates. Neutrophil-related chemokines were upregulated in APS immunoglobulin G-stimulated HCAECs, consistent with increased neutrophil infiltration and neutrophil extracellular traps formation in vivo. CONCLUSION: Our findings suggest that patients with aPL-positive AMI represent a distinct AMI subset with worse outcomes. They may benefit from additional therapies beyond standard treatment. Neutrophil-driven inflammatory pathways could be a potential underlying mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, AntiphospholipidMyocardial InfarctionAntiphospholipid SyndromeHumansMaleAnimalsFemaleMiddle AgedPrognosisAgedEndothelial CellsDisease Models, AnimalRisk FactorsAdultNeutrophilsMiceCells, CulturedBiomarkersExtracellular Traps

Stichwörter der Autor:innen

antiphospholipid antibodyantiphospholipid syndromemyocardial infarctionneutrophilneutrophil extracellular traps

Substanzen

Antibodies, AntiphospholipidBiomarkers

Autor:innen und Institutionen

  • Center of Laboratory Medicine, Beijing Key Laboratory of Cardiovascular Disease Warning and Diagnosis, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union M…

Förderung

  • Beijing Natural Science Foundation
  • National Natural Science Foundation of China
  • Chinese Academy of Medical Sciences
  • Fuwai Hospital, Chinese Academy of Medical Sciences
  • Peking Union Medical College

Zitieren

APA

Bayartaikishigtai, D., Pei, S., Chen, Z., Luo, F., Xu, J., Song, D., Yu, D., Xu, Q., Wang, X., Liu, J., Zhang, Y., & Zhou, Z. (2026). Exploring the prognostic significance of antiphospholipid antibody in acute myocardial infarction: insights from clinical study and mechanism. Journal of Thrombosis and Haemostasis, 24(4), 1425-1437. https://doi.org/10.1016/j.jtha.2025.12.026

Vancouver

Bayartaikishigtai D, Pei S, Chen Z, Luo F, Xu J, Song D, et al. Exploring the prognostic significance of antiphospholipid antibody in acute myocardial infarction: insights from clinical study and mechanism. Journal of Thrombosis and Haemostasis. 2026;24(4):1425-1437. doi:10.1016/j.jtha.2025.12.026

BibTeX
@article{Bayartaikishigtai2026,
  author = {Bayartaikishigtai, Dabuxilite and Pei, Shengqiang and Chen, Zixin and Luo, Fengming and Xu, Jie and Song, Danyu and Yu, Dongze and Xu, Qiang and Wang, Ximing and Liu, Jianru and Zhang, Yang and Zhou, Zhou},
  title = {Exploring the prognostic significance of antiphospholipid antibody in acute myocardial infarction: insights from clinical study and mechanism},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {1425--1437},
  doi = {10.1016/j.jtha.2025.12.026}
}
Kostenlos starten →